Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
Identifieur interne : 001646 ( PubMed/Corpus ); précédent : 001645; suivant : 001647Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
Auteurs : Jian Tang ; Naru Zhang ; Xinrong Tao ; Guangyu Zhao ; Yan Guo ; Chien-Te K. Tseng ; Shibo Jiang ; Lanying Du ; Yusen ZhouSource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2015.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Antigens, Viral (administration & dosage), Antigens, Viral (genetics), Antigens, Viral (immunology), Coronavirus Infections (prevention & control), Female, Humans, Immunity, Cellular, Immunity, Humoral, Immunoglobulin Fc Fragments (administration & dosage), Immunoglobulin Fc Fragments (genetics), Immunoglobulin Fc Fragments (immunology), Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus (immunology), Polysorbates (administration & dosage), Recombinant Fusion Proteins (administration & dosage), Recombinant Fusion Proteins (genetics), Recombinant Fusion Proteins (immunology), Squalene (administration & dosage), Vaccines, Subunit (administration & dosage), Vaccines, Subunit (genetics), Vaccines, Subunit (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Antigens, Viral, Immunoglobulin Fc Fragments, Polysorbates, Recombinant Fusion Proteins, Squalene, Vaccines, Subunit, Viral Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , genetics : Antigens, Viral, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins, Vaccines, Subunit, Viral Vaccines.
- chemical , immunology : Antigens, Viral, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins, Vaccines, Subunit, Viral Vaccines.
- immunology : Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- Animals, Female, Humans, Immunity, Cellular, Immunity, Humoral, Mice, Inbred BALB C.
Abstract
Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a serious threat to public health worldwide, calling for development of safe and effective MERS vaccines. We have previously shown that a recombinant protein containing residues 377-588 of MERS-CoV receptor-binding domain (RBD) fused with human Fc (S377-588-Fc) induced highly potent anti-MERS-CoV neutralizing antibodies in the presence of MF59 adjuvant. Here we optimized the doses of S377-588-Fc using MF59 as an adjuvant in order to elicit strong immune responses with minimal amount of antigen. Our results showed that S377-588-Fc at 1 μg was able to induce in the immunized mice potent humoral and cellular immune responses. Particularly, S377-588-Fc at 1 μg elicited strong neutralizing antibody responses against both pseudotyped and live MERS-CoV similar to those induced at 5 and 20 μg, respectively. These results suggest that this RBD-based subunit MERS vaccine candidate at the dose as low as one μg is sufficiently potent to induce strong humoral and cellular immune responses, including neutralizing antibodies, against MERS-CoV infection, thus providing guidance for determining the optimal dosage of RBD-based MERS vaccines in the future clinical trials and for applying the dose-sparing strategy in other subunit vaccine trials.
DOI: 10.1080/21645515.2015.1021527
PubMed: 25874632
Links to Exploration step
pubmed:25874632Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.</title><author><name sortKey="Tang, Jian" sort="Tang, Jian" uniqKey="Tang J" first="Jian" last="Tang">Jian Tang</name><affiliation><nlm:affiliation>a Xiang-Ya Medical College; Central South University; , Changsha , China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Naru" sort="Zhang, Naru" uniqKey="Zhang N" first="Naru" last="Zhang">Naru Zhang</name></author><author><name sortKey="Tao, Xinrong" sort="Tao, Xinrong" uniqKey="Tao X" first="Xinrong" last="Tao">Xinrong Tao</name></author><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name></author><author><name sortKey="Guo, Yan" sort="Guo, Yan" uniqKey="Guo Y" first="Yan" last="Guo">Yan Guo</name></author><author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25874632</idno><idno type="pmid">25874632</idno><idno type="doi">10.1080/21645515.2015.1021527</idno><idno type="wicri:Area/PubMed/Corpus">001646</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001646</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.</title><author><name sortKey="Tang, Jian" sort="Tang, Jian" uniqKey="Tang J" first="Jian" last="Tang">Jian Tang</name><affiliation><nlm:affiliation>a Xiang-Ya Medical College; Central South University; , Changsha , China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Naru" sort="Zhang, Naru" uniqKey="Zhang N" first="Naru" last="Zhang">Naru Zhang</name></author><author><name sortKey="Tao, Xinrong" sort="Tao, Xinrong" uniqKey="Tao X" first="Xinrong" last="Tao">Xinrong Tao</name></author><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name></author><author><name sortKey="Guo, Yan" sort="Guo, Yan" uniqKey="Guo Y" first="Yan" last="Guo">Yan Guo</name></author><author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Antigens, Viral (administration & dosage)</term><term>Antigens, Viral (genetics)</term><term>Antigens, Viral (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Female</term><term>Humans</term><term>Immunity, Cellular</term><term>Immunity, Humoral</term><term>Immunoglobulin Fc Fragments (administration & dosage)</term><term>Immunoglobulin Fc Fragments (genetics)</term><term>Immunoglobulin Fc Fragments (immunology)</term><term>Mice, Inbred BALB C</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>Polysorbates (administration & dosage)</term><term>Recombinant Fusion Proteins (administration & dosage)</term><term>Recombinant Fusion Proteins (genetics)</term><term>Recombinant Fusion Proteins (immunology)</term><term>Squalene (administration & dosage)</term><term>Vaccines, Subunit (administration & dosage)</term><term>Vaccines, Subunit (genetics)</term><term>Vaccines, Subunit (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Antigens, Viral</term><term>Immunoglobulin Fc Fragments</term><term>Polysorbates</term><term>Recombinant Fusion Proteins</term><term>Squalene</term><term>Vaccines, Subunit</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term><term>Immunoglobulin Fc Fragments</term><term>Recombinant Fusion Proteins</term><term>Vaccines, Subunit</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>Immunoglobulin Fc Fragments</term><term>Recombinant Fusion Proteins</term><term>Vaccines, Subunit</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Humans</term><term>Immunity, Cellular</term><term>Immunity, Humoral</term><term>Mice, Inbred BALB C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a serious threat to public health worldwide, calling for development of safe and effective MERS vaccines. We have previously shown that a recombinant protein containing residues 377-588 of MERS-CoV receptor-binding domain (RBD) fused with human Fc (S377-588-Fc) induced highly potent anti-MERS-CoV neutralizing antibodies in the presence of MF59 adjuvant. Here we optimized the doses of S377-588-Fc using MF59 as an adjuvant in order to elicit strong immune responses with minimal amount of antigen. Our results showed that S377-588-Fc at 1 μg was able to induce in the immunized mice potent humoral and cellular immune responses. Particularly, S377-588-Fc at 1 μg elicited strong neutralizing antibody responses against both pseudotyped and live MERS-CoV similar to those induced at 5 and 20 μg, respectively. These results suggest that this RBD-based subunit MERS vaccine candidate at the dose as low as one μg is sufficiently potent to induce strong humoral and cellular immune responses, including neutralizing antibodies, against MERS-CoV infection, thus providing guidance for determining the optimal dosage of RBD-based MERS vaccines in the future clinical trials and for applying the dose-sparing strategy in other subunit vaccine trials.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25874632</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.</ArticleTitle><Pagination><MedlinePgn>1244-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1021527</ELocationID><Abstract><AbstractText>Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a serious threat to public health worldwide, calling for development of safe and effective MERS vaccines. We have previously shown that a recombinant protein containing residues 377-588 of MERS-CoV receptor-binding domain (RBD) fused with human Fc (S377-588-Fc) induced highly potent anti-MERS-CoV neutralizing antibodies in the presence of MF59 adjuvant. Here we optimized the doses of S377-588-Fc using MF59 as an adjuvant in order to elicit strong immune responses with minimal amount of antigen. Our results showed that S377-588-Fc at 1 μg was able to induce in the immunized mice potent humoral and cellular immune responses. Particularly, S377-588-Fc at 1 μg elicited strong neutralizing antibody responses against both pseudotyped and live MERS-CoV similar to those induced at 5 and 20 μg, respectively. These results suggest that this RBD-based subunit MERS vaccine candidate at the dose as low as one μg is sufficiently potent to induce strong humoral and cellular immune responses, including neutralizing antibodies, against MERS-CoV infection, thus providing guidance for determining the optimal dosage of RBD-based MERS vaccines in the future clinical trials and for applying the dose-sparing strategy in other subunit vaccine trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a Xiang-Ya Medical College; Central South University; , Changsha , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Naru</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Xinrong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guangyu</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chien-Te K</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shibo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Lanying</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yusen</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI109094</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AI109094</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007141">Immunoglobulin Fc Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007141" MajorTopicYN="N">Immunoglobulin Fc Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MERS</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">antigen doses</Keyword><Keyword MajorTopicYN="N">receptor-binding domain</Keyword><Keyword MajorTopicYN="N">subunit vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25874632</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1021527</ArticleId><ArticleId IdType="pmc">PMC4514392</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Jun 27;368(26):2487-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23718156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Oct 14;32(45):5975-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25192975</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2013 Sep;17(9):e668-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23916548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Sep;87(17):9939-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23824801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Sep;87(17):9953-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23824802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):745-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23782859</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Oct;87(19):10777-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23903833</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2013;10:266</Citation><ArticleIdList><ArticleId IdType="pubmed">23978242</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2013;4(5):e00650-13</Citation><ArticleIdList><ArticleId IdType="pubmed">24023385</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2013 Oct;19(10):1697-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24050621</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Oct 21;32(46):6170-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25240756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1999 Nov;180(5):1700-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10515836</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2006 Sep;58(3):621-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16968952</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Jan 15;180(2):948-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18178835</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Mar 20;26(13):1644-51</Citation><ArticleIdList><ArticleId IdType="pubmed">18289745</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jun 19;26(26):3209-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18462843</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2010 Jul 2;397(3):580-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20617558</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Mar 1;203(5):666-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21282194</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e53568</Citation><ArticleIdList><ArticleId IdType="pubmed">23320093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2015 Feb;17(2):123-34</Citation><ArticleIdList><ArticleId IdType="pubmed">25529753</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2015 Apr 16;202:151-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25445336</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Oct;13(10):859-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23933067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Nov;87(21):11950-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23986586</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Oct 31;369(18):1761</Citation><ArticleIdList><ArticleId IdType="pubmed">24171525</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2013 Nov;5(11):2679-89</Citation><ArticleIdList><ArticleId IdType="pubmed">24184965</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Dec;87(24):13134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">24067982</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(12):e81587</Citation><ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2014;5:3067</Citation><ArticleIdList><ArticleId IdType="pubmed">24473083</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 May 30;32(26):3169-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2014 Jun;13(6):761-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24766432</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation><ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2014;5(4):e01450-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25053787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Jun;88(12):7045-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24719424</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12516-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25114257</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2016 Mar;13(2):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001646 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001646 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25874632
|texte= Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25874632" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |